News UCB closes on first EU OK for TK2d therapy UCB gets an EU recommendation for the first therapy for thymidine kinase 2 deficiency (TK2d), plus other CHMP decisions.
News Gedeon Richter brings HRT option back to the UK market After a 17-year absence, a dydrogesterone-only hormone replacement therapy (HRT) formulation is available again in the UK market.
News 'Transformational' pill for endometriosis gets NHS nod Around 1,000 women in England a year with endometriosis will soon have access to the first daily oral therapy, Gedeon Richter's Ryeqo, via the NHS.
News Gedeon Richter gets NICE nod for uterine fibroids drug Ryeqo Around 4,500 women in the UK will be eligible for treatment with Gedeon Richter's once-daily oral therapy Ryeqo, after NICE backed the GnRH antagonist to treat heavy menstrual bleeding asso
News Allergan and Gedeon Richter set to expand use of bipolar dru... Companies want Vraylar as option bipolar depression
Patients LSX2026: On promise and patience, with Hans Schambye At LSX World Congress 2026 in Lisbon, Portugal, web editor Nicole Raleigh spoke with Hans Schambye, CEO of BOOST Pharma.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
